The department of Stem Cell Biology at Hagedorn Research Institute consists of highly motivated and enthusiastic scientists, post docs, lab technicians, Ph.D. and M.Sc. students.
Our aim is to develop cell replacement therapy into a viable option for treating Diabetes Mellitus. The reconstitution of a functional beta cell mass can restore blood glucose homeostasis in diabetic patients and eliminates the need for insulin injections. A tight regulation of the blood glucose level reduces the risk of developing secondary complications. However, the lack of transplantable beta cells is delaying progress in this field. Our main objective is to generate clinical-grade pancreatic beta cells from pluripotent stem cells by harnessing their differentiation potential and to recapitulate the complex process of beta cell formation in vitro. We are collaborating with world-leading academic as well as industrial partners to achieve this goal, including a joint project with Harvard Stem Cell Institute on diabetes disease modeling using induced pluripotent stem cells. Furthermore, we work in close collaboration with our colleagues in the department of Beta Cell Regeneration as well as the scientists in Diabetes Biology and Pharmacology and Diabetes Protein Engineering